Last reviewed · How we verify
No DMTs
At a glance
| Generic name | No DMTs |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis
- Evaluation of the Dexmedetomidine Transdermal Systems for Postoperative Analgesia Following Abdominoplasty (PHASE2)
- Libyan Multiple Sclerosis Registry Study
- Pediatric Spinal Muscular Atrophy (SMA) China Registry
- Adult Spinal Muscular Atrophy (SMA) China Registry
- Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC) (PHASE4)
- Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multiple Sclerosis (MS) Vaccination Study
- Longitudinal Data Collection in Pediatric and Adult Patients With Spinal Muscular Atrophy in Latin America
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- No DMTs CI brief — competitive landscape report
- No DMTs updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI